[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid19-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid19-infection":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100543389",false,"NCT06355232","Covid-19 and Influenza Oral Vaccine Study","A Binded, Randomised, Controlled Cross-over Trial to Assess the Safety and Efficacy of Mucosal Covid-19 and Influenza Vaccines","Inclusion Criteria:\n\n* Able to provide written informed consent\n* Males or females 18 years of age or older\n* Understand and are likely to comply with planned study procedures and be available for all study visits.\n* Do not plan to have a non-study COVID-19 or influenza vaccine within the next 6 months.\n\nExclusion Criteria:\n\n* Allergy to COVID-19 or seasonal influenza vaccine or one of its components e.g. polysorbate 80.\n* Have received a COVID-19 or influenza vaccine or an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent or a COVID-19 or influenza vaccine during the trial reporting period.\n* Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral\u002F sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.",[26,27],"covid19 Infection","Influenza, Human",[29,30,31,32,33,34,35,36],"covid-19","influenza","pandemic","mucosal","spikogen","advax","adjuvant","vaccine","RECRUITING","2025-09-16",{"date":40,"type":41},"2025-09-17","ACTUAL",{"date":43,"type":41},"2024-05-01",{"date":45,"type":20},"2026-12-31",{"name":47,"class":48},"Vaxine Pty Ltd","INDUSTRY",""]